Guardian Pharmacy Services, Inc. (GRDN)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Guardian Pharmacy Services, Inc. (GRDN) trades at $40.48 with AI Score 98/100 (Grade A+). Guardian Pharmacy Services, Inc. Market cap: $2.56B, Sector: Healthcare.
Price live · AI analysis from May 6, 2026GRDN stock analysis for 2026: Analysts have set a consensus price target of $38.00 for Guardian Pharmacy Services, Inc., suggesting 6.1% downside from the current price of $40.48. The AI MoonshotScore is 98/100, indicating a strong bullish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
GRDN: 6/7 perspectives are bullish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Guardian Pharmacy Services, Inc. (GRDN) Healthcare & Pipeline Overview
Guardian Pharmacy Services provides technology-enabled pharmacy solutions for long-term care facilities in the U.S., specializing in lower acuity settings like assisted living and behavioral health facilities. Their services include clinical support, drug dispensing, and administration, enhanced by their Guardian Compass data analytics platform, positioning them as a key player in the medical distribution sector.
What Is the Investment Thesis for GRDN?
Guardian Pharmacy Services presents a notable research candidate within the growing long-term care market. The company's focus on lower acuity LTCFs, a segment often underserved by larger pharmacy providers, allows for specialized service offerings and stronger customer relationships. With a P/E ratio of 46.8 and a profit margin of 3.6%, there is room for improvement in profitability through operational efficiencies and strategic pricing. The company's beta of 0.47 suggests lower volatility compared to the overall market, making it a potentially stable investment. Key growth catalysts include expanding their Guardian Compass platform to offer more advanced analytics and integrating additional clinical services to enhance patient care. The increasing demand for LTCF services, driven by the aging population, further supports the investment thesis. Ultimately, Guardian Pharmacy Services' technology-enabled solutions and focus on a specific market segment position it for sustained growth and value creation.
Based on FMP financials and quantitative analysis
GRDN Key Highlights
- Market Cap of $2.56B indicates a significant presence in the healthcare sector.
- P/E Ratio of 46.8 suggests investors are paying a premium for its earnings, reflecting growth expectations.
- Profit Margin of 3.6% shows room for improvement compared to industry leaders.
- Gross Margin of 20.2% demonstrates the profitability of its core pharmacy services.
- Beta of 0.47 indicates lower volatility compared to the broader market, suggesting a relatively stable investment.
Who Are GRDN's Competitors?
GRDN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| EWTX Edgewise Therapeutics, Inc. | $43.13 | +7.56% | $4.64B | 71 |
| FEDDX Fidelity Emerging Markets Discovery Fd | $23.32 | +1.83% | $1.53B | 47 |
| DAUG FT Vest U.S. Equity Deep Buffer ETF - August | $47.01 | +0.09% | $363.75M | 47 |
| KSTR KraneShares SSE STAR Market 50 Index ETF | $28.60 | +0.25% | $66.71M | 47 |
| PEQSX Putnam Large Cap Value Fund | $44.15 | +0.46% | $51.63B | 47 |
| CWB State Street SPDR Bloomberg Convertible Securities ETF | $104.07 | -1.20% | $4.57B | 47 |
| TDV ProShares - S&P Technology Dividend Aristocrats ETF | $97.90 | -2.62% | $276.99M | 47 |
| EVPF Eaton Vance Preferred Securities and Income ETF | $50.26 | -0.22% | $17.78M | 46 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GRDN's Key Strengths?
- Specialized expertise in serving lower acuity LTCFs.
- Technology-enabled solutions for efficient pharmacy operations.
- Strong relationships with LTCF providers.
- Comprehensive suite of clinical and administrative services.
What Are GRDN's Weaknesses?
- Relatively low profit margin compared to industry leaders.
- Dependence on reimbursement rates and regulatory environment.
- Limited brand recognition outside of the LTCF market.
- Potential for increased competition from larger pharmacy chains.
What Could Drive GRDN Stock Higher?
- Expansion of Guardian Compass platform to include advanced analytics and predictive modeling.
- Increasing demand for LTCF services due to the aging population.
- Strategic partnerships with LTCF providers to integrate pharmacy services into care delivery models.
What Are the Key Risks for GRDN?
- Rich valuation — a P/E of 46.8 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
- Changes in government regulations and reimbursement policies impacting pharmacy revenue.
- Increased competition from larger pharmacy chains entering the LTCF market.
- Economic downturn affecting LTCF occupancy rates and ability to pay for services.
- Potential for medication errors and associated liability claims.
What Are the Growth Opportunities for GRDN?
- Expansion into New Geographic Markets: Guardian Pharmacy Services has the opportunity to expand its geographic footprint by targeting underserved regions with a high concentration of LTCFs. This expansion could involve establishing new pharmacy locations or acquiring existing regional pharmacy providers. The market for LTCF pharmacy services is estimated to be worth billions of dollars annually, and by strategically expanding into new markets, Guardian can capture a larger share of this growing market. Timeline: Ongoing.
- Enhancement of Technology Platform: Investing in and enhancing the Guardian Compass platform can provide significant growth opportunities. By incorporating advanced analytics, predictive modeling, and real-time monitoring capabilities, Guardian can offer LTCFs more actionable insights to improve patient care, reduce costs, and optimize medication management. This enhanced technology platform can also attract new customers and differentiate Guardian from its competitors. Timeline: Ongoing.
- Development of Specialized Clinical Programs: Creating and implementing specialized clinical programs tailored to specific patient populations within LTCFs can drive growth and improve patient outcomes. These programs could focus on areas such as medication adherence, chronic disease management, and pain management. By offering these specialized programs, Guardian can demonstrate its value to LTCFs and attract new customers seeking comprehensive pharmacy solutions. Timeline: Ongoing.
- Strategic Partnerships with LTCF Providers: Forming strategic partnerships with LTCF providers can create mutually beneficial growth opportunities. These partnerships could involve integrating Guardian's pharmacy services into the LTCF's care delivery model, collaborating on research initiatives, and developing joint marketing programs. By aligning its interests with those of LTCF providers, Guardian can strengthen its customer relationships and drive long-term growth. Timeline: Ongoing.
- Acquisition of Smaller Regional Pharmacies: Guardian Pharmacy Services can pursue a growth strategy through the acquisition of smaller regional pharmacies that serve the LTCF market. These acquisitions can provide Guardian with access to new markets, customers, and talent. By integrating these acquired pharmacies into its existing network, Guardian can achieve economies of scale and improve its overall operational efficiency. Timeline: Ongoing.
What Opportunities Does GRDN Have?
- Expansion into new geographic markets.
- Development of specialized clinical programs.
- Strategic partnerships with LTCF providers.
- Acquisition of smaller regional pharmacies.
What Threats Does GRDN Face?
- Changes in government regulations and reimbursement policies.
- Increased competition from larger pharmacy chains.
- Economic downturn affecting LTCF occupancy rates.
- Potential for medication errors and liability claims.
What Are GRDN's Competitive Advantages?
- Specialized focus on lower acuity LTCFs allows for tailored service offerings.
- Technology-enabled solutions, such as Guardian Compass, provide a competitive advantage.
- Strong relationships with LTCF providers create customer loyalty.
- Scalable business model allows for efficient expansion into new markets.
What Does GRDN Do?
Founded in 2003 and headquartered in Atlanta, Georgia, Guardian Pharmacy Services, Inc. has established itself as a leading provider of pharmacy services tailored to the long-term care facility (LTCF) market. The company recognized a need for specialized pharmacy solutions that cater to the unique requirements of residents in lower acuity LTCFs, such as assisted living facilities, behavioral health facilities, and group homes. Unlike traditional pharmacies, Guardian Pharmacy Services focuses on delivering individualized clinical, drug dispensing, and administration capabilities designed to improve patient outcomes and streamline operations for LTCFs. Their comprehensive suite of services includes medication therapy management, adherence programs, and specialized packaging to ensure accurate and timely medication delivery. A key differentiator is their technology-driven approach, exemplified by Guardian Compass, a proprietary data analytics platform that provides local pharmacies with real-time insights to optimize business operations, track performance, and enhance patient care. Furthermore, the GuardianShield Programs offer LTCFs additional support in areas such as regulatory compliance, risk management, and staff training. With approximately 3,400 employees, Guardian Pharmacy Services operates a network of pharmacies across the United States, serving a diverse range of LTCFs and solidifying its position as a trusted partner in the long-term care industry.
What Products and Services Does GRDN Offer?
- Provide technology-enabled pharmacy services to long-term care facilities (LTCFs).
- Offer individualized clinical services to residents in lower acuity LTCFs.
- Dispense and administer medications to residents in LTCFs.
- Provide data-driven insights through their Guardian Compass platform.
- Offer GuardianShield Programs for LTCFs, focusing on regulatory compliance and risk management.
- Support assisted living facilities, behavioral health facilities, and group homes with specialized pharmacy solutions.
How Does GRDN Make Money?
- Generate revenue through dispensing prescription medications to residents in LTCFs.
- Offer clinical services, such as medication therapy management and adherence programs, for additional fees.
- Provide technology solutions, such as the Guardian Compass platform, on a subscription basis.
- Partner with LTCFs to provide comprehensive pharmacy services and share in cost savings.
What Industry Does GRDN Operate In?
Guardian Pharmacy Services operates within the medical distribution industry, specifically focusing on the long-term care pharmacy market. This market is experiencing growth due to the aging population and increasing demand for LTCF services. The competitive landscape includes both large national pharmacy chains and smaller regional providers. Guardian differentiates itself through its technology-enabled solutions, specialized services for lower acuity LTCFs, and data-driven approach to optimizing pharmacy operations. The industry is also subject to regulatory changes and reimbursement pressures, requiring companies to adapt and innovate to maintain profitability.
Who Are GRDN's Key Customers?
- Assisted living facilities (ALFs).
- Behavioral health facilities.
- Group homes.
- Other lower acuity long-term care facilities.
FY2026 estForward Outlook
Wall Street analysts project Guardian Pharmacy Services, Inc. revenue of about $1.41B for fiscal 2026, with EPS near $1.26. The estimate reflects 4 contributing analysts.
GRDN Valuation & Market Position
With a $2.56B market cap, Guardian Pharmacy Services, Inc. sits in the mid-cap segment of the market. Relative to its peer group, GRDN's quantitative score of 98/100 is above the peer average of 52/100.
ROE 27%Key Financial Metrics
Return on equity for Guardian Pharmacy Services, Inc. stands at 27.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 12.4%, showing how much profit it generates from its asset base. GRDN trades at a trailing price-to-earnings ratio of 46.85, above the Healthcare sector average of ~23x. Its free cash flow yield is 2.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.46 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.2%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 6/9Financial Health
Guardian Pharmacy Services, Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 12.30 places it in the safe zone, indicating low near-term bankruptcy risk.
Company Profile
Guardian Pharmacy Services, Inc. operates in the Medical - Distribution industry within the Healthcare sector. It is headquartered in Atlanta, US. The company is led by CEO Fred Burke. GRDN has traded publicly since 2016.
GRDN Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that those closest to the business see potential upside.
- Community sentiment has shifted positively, with discussions highlighting the company's strong service offerings and growth in the pharmacy sector.
- Analysts are noting increasing demand for pharmacy services, particularly in elder care, which could benefit Guardian significantly.
- Recent partnerships with healthcare providers have been well-received, suggesting a strong market position and potential for revenue growth.
Bear Case
- Concerns about regulatory challenges in the pharmacy sector have surfaced, creating uncertainty around operational costs and compliance.
- Some community members express skepticism about the company's ability to scale effectively in a competitive market, which could limit growth.
- Recent market developments indicate potential disruptions from telehealth services, which may affect traditional pharmacy operations.
- Negative sentiment from investors regarding overall healthcare stock performance could weigh on Guardian's stock, as it is often viewed within that broader context.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
GRDN Latest News
-
Guardian Pharmacy's Site Tour Reinforces Confidence in Prospects, BofA Says
MT Newswires · Jun 17, 2026
-
Statutory Profit Doesn't Reflect How Good Guardian Pharmacy Services' (NYSE:GRDN) Earnings Are
Yahoo! Finance: GRDN News · May 14, 2026
-
Guardian Pharmacy Services, Inc. (GRDN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
seekingalpha.com · May 13, 2026
-
Guardian Pharmacy Services Q1 Earnings Call Highlights
marketbeat.com · May 10, 2026
GRDN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GRDN.
Price Targets
Consensus target: $38.00
GRDN MoonshotScore
What does this score mean?
The MoonshotScore rates GRDN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Guardian Pharmacy's Site Tour Reinforces Confidence in Prospects, BofA Says
Statutory Profit Doesn't Reflect How Good Guardian Pharmacy Services' (NYSE:GRDN) Earnings Are
Guardian Pharmacy Services, Inc. (GRDN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Guardian Pharmacy Services Q1 Earnings Call Highlights
Latest Guardian Pharmacy Services, Inc. Analysis
Leadership: Fred Burke
CEO
Fred Burke serves as the CEO of Guardian Pharmacy Services, bringing extensive experience in healthcare management and operations. Prior to joining Guardian, Burke held leadership positions at various healthcare organizations, where he focused on improving patient care and driving operational efficiency. His background includes expertise in pharmacy services, long-term care, and healthcare technology. Burke's leadership is characterized by a commitment to innovation, customer service, and employee engagement. He holds a degree in Business Administration and has completed executive education programs at leading universities.
Track Record: Under Fred Burke's leadership, Guardian Pharmacy Services has experienced significant growth and expansion. He has overseen the implementation of key strategic initiatives, including the development of the Guardian Compass platform and the expansion into new geographic markets. Burke has also focused on strengthening the company's relationships with LTCF providers and improving patient outcomes. His leadership has been instrumental in establishing Guardian Pharmacy Services as a leading provider of pharmacy services in the long-term care market.
What Investors Ask About Guardian Pharmacy Services, Inc. (GRDN) — Healthcare
What does Guardian Pharmacy Services, Inc. do?
Guardian Pharmacy Services, Inc. provides technology-enabled pharmacy services to residents in long-term health care facilities (LTCFs) across the United States. They specialize in serving lower acuity LTCFs, such as assisted living facilities and behavioral health facilities, offering individualized clinical, drug dispensing, and administration capabilities. Their core offering includes the Guardian Compass platform, which leverages data analytics to optimize pharmacy operations and improve patient care. By focusing on the unique needs of LTCFs, Guardian Pharmacy Services aims to enhance medication management, reduce costs, and improve the overall quality of care for residents.
What are the main risks for GRDN?
Guardian Pharmacy Services, Inc. faces several risks inherent to the healthcare and pharmaceutical industries. Changes in government regulations and reimbursement policies, particularly those related to Medicare and Medicaid, could significantly impact the company's revenue and profitability. Increased competition from larger pharmacy chains and other LTCF pharmacy providers could also erode market share. Additionally, economic downturns could affect LTCF occupancy rates and the ability of residents to pay for services. The company also faces the risk of medication errors and associated liability claims, which could damage its reputation and financial performance. Effective risk management and compliance programs are essential to mitigating these potential challenges.
What are the key factors to evaluate for GRDN?
Guardian Pharmacy Services, Inc. (GRDN) holds an AI score of 98/100 (high). P/E: 46.8x vs the S&P 500's ~20-25x. Analysts target $38.00 (-6%). Not financial advice.
How frequently does GRDN data refresh on this page?
GRDN prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven GRDN's recent stock price performance?
Guardian Pharmacy Services, Inc. (GRDN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized expertise in serving lower acuity LTCFs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GRDN overvalued or undervalued right now?
Guardian Pharmacy Services, Inc. (GRDN) trades at 46.8x earnings. Analysts target $38.00 (-6%) — near fair value. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying GRDN?
Before investing in Guardian Pharmacy Services, Inc. (GRDN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding GRDN to a portfolio?
Key strength of Guardian Pharmacy Services, Inc. (GRDN): Specialized expertise in serving lower acuity LTCFs. Its MoonshotScore of 98/100 reflects strong quantitative fundamentals. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-05-06.
- Analyst consensus may vary depending on the source and timing of the analysis.
- Investment decisions should be based on individual risk tolerance and financial circumstances.